Epithelial presenilin-1 drives colorectal tumour growth by controlling EGFR-COX2 signalling

Objective Psen1 was previously characterised as a crucial factor in the pathogenesis of neurodegeneration in patients with Alzheimer’s disease. Little, if any, is known about its function in the gut. Here, we uncovered an unexpected functional role of Psen1 in gut epithelial cells during intestinal tumourigenesis. Design Human colorectal cancer (CRC) and control samples were investigated for PSEN1 and proteins of theγ-secretase complex. Tumour formation was analysed in the AOM-DSS and Apc min/+ mouse models using newly generated epithelial-specific Psen1 deficient mice. Psen1 deficient human CRC cells were studied in a xenograft tumour model. Tumour-derived organoids were analysed for growth and RNA-Seq was performed to identify Psen1-regulated pathways. Tumouroids were generated to study EGFR activation and evaluation of the influence of prostanoids. Results PSEN1 is expressed in the intestinal epithelium and its level is increased in human CRC. Psen1-deficient mice developed only small tumours and human cancer cell lines deficient in Psen1 had a reduced tumourigenicity. Tumouroids derived from Psen1-deficient Apc min/+ mice exhibited stunted growth and reduced cell proliferation. On a molecular level, PSEN1 potentiated tumour cell proliferation via enhanced EGFR signalling and COX-2 production. Exogenous administration of PGE2 reversed the slow growth of PSEN1 deficient tumour cells via PGE2 receptor 4 (EP4) receptor signalling. Conclusions Psen1 drives tumour development by increasing EGFR signalling via NOTCH1 processing, and by activating the COX-2-PGE2 pathway. PSEN1 inhibition could be a useful strategy in treatment of CRC.

[1]  M. Neurath,et al.  E-type prostanoid receptor 4 drives resolution of intestinal inflammation by blocking epithelial necroptosis , 2021, Nature Cell Biology.

[2]  C. Damodaran,et al.  A Review on Notch Signaling and Colorectal Cancer , 2020, Cells.

[3]  Y. Kluger,et al.  Paracrine orchestration of intestinal tumorigenesis by a mesenchymal niche , 2020, Nature.

[4]  H. D. de Koning,et al.  Impact of colorectal cancer screening on cancer-specific mortality in Europe: A systematic review. , 2020, European journal of cancer.

[5]  L. Sangaré,et al.  A Multinational Assessment of Gastric, Esophageal, and Colorectal Cancer Burden: A Report of Disease Incidence, Prevalence, and Fatality , 2019, Journal of Gastrointestinal Cancer.

[6]  D. Cunningham,et al.  Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution. , 2019, Critical reviews in oncology/hematology.

[7]  J. Cashman,et al.  Disruption of NOTCH signaling by a small molecule inhibitor of the transcription factor RBPJ , 2019, Scientific Reports.

[8]  Ke Chen,et al.  Indometacin inhibits the proliferation and activation of human pancreatic stellate cells through the downregulation of COX-2. , 2018, Oncology reports.

[9]  Yarden Katz,et al.  A single-cell survey of the small intestinal epithelium , 2017, Nature.

[10]  Yi-Hsin Yang,et al.  Role of cyclooxygenase‐2 inhibitors in the survival outcome of colorectal cancer patients: A population‐based cohort study , 2017, The Kaohsiung journal of medical sciences.

[11]  Cheng Li,et al.  GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses , 2017, Nucleic Acids Res..

[12]  Jun Chen,et al.  Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth , 2016, Molecular Cancer Therapeutics.

[13]  Z. Fan,et al.  Identification and validation of COX-2 as a co-target for overcoming cetuximab resistance in colorectal cancer cells , 2016, Oncotarget.

[14]  Yun Li,et al.  The expression of presenilin 1 enhances carcinogenesis and metastasis in gastric cancer , 2016, Oncotarget.

[15]  Na Li,et al.  Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells. , 2015, International journal of clinical and experimental pathology.

[16]  C. Osipo,et al.  Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer , 2014, Front. Oncol..

[17]  D. Elashoff,et al.  Targeted Cox2 gene deletion in intestinal epithelial cells decreases tumorigenesis in female, but not male, ApcMin/+ mice , 2014, Molecular oncology.

[18]  T. Golde,et al.  γ-Secretase inhibitors and modulators. , 2013, Biochimica et biophysica acta.

[19]  R. DuBois,et al.  An Inflammatory Mediator, Prostaglandin E2, in Colorectal Cancer , 2013, Cancer journal.

[20]  Weihong Song,et al.  Biological function of Presenilin and its role in AD pathogenesis , 2013, Translational Neurodegeneration.

[21]  A. Krešo,et al.  Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer , 2012, Oncogene.

[22]  M. Chilosi,et al.  Use of Immunohistochemistry Techniques in Patients Exposed to Sulphur Mustard Gas , 2011, Pathology research international.

[23]  A. Krasinskas.  EGFR Signaling in Colorectal Carcinoma , 2011, Pathology research international.

[24]  M. Neurath,et al.  Assessment of tumor development and wound healing using endoscopic techniques in mice. , 2010, Gastroenterology.

[25]  R. DuBois,et al.  The role of COX-2 in intestinal inflammation and colorectal cancer , 2010, Oncogene.

[26]  F. Ali-Osman,et al.  Cyclooxygenase-2 Is a Novel Transcriptional Target of the Nuclear EGFR-STAT3 and EGFRvIII-STAT3 Signaling Axes , 2010, Molecular Cancer Research.

[27]  Q. Su,et al.  Notch-1 regulates transcription of the epidermal growth factor receptor through p53. , 2008, Carcinogenesis.

[28]  D. Kang,et al.  Presenilin 1 Regulates Epidermal Growth Factor Receptor Turnover and Signaling in the Endosomal-Lysosomal Pathway* , 2007, Journal of Biological Chemistry.

[29]  Bin Liu,et al.  Epidermal Growth Factor Receptor Activation: An Upstream Signal for Transition of Quiescent Astrocytes into Reactive Astrocytes after Neural Injury , 2006, The Journal of Neuroscience.

[30]  A. C. Williams,et al.  Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence. , 2006, Cancer research.

[31]  Stefan Wirtz,et al.  TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling , 2004 .

[32]  D. Simmons,et al.  The cyclooxygenases , 2004, Genome Biology.

[33]  R. Kiesslich,et al.  TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. , 2004, Immunity.

[34]  R. DuBois,et al.  COX-2 inhibition and colorectal cancer. , 2004, Seminars in oncology.

[35]  R. Young,et al.  Discovery of a potent and selective agonist of the prostaglandin EP4 receptor. , 2003, Bioorganic & medicinal chemistry letters.

[36]  E. Kandel,et al.  APP Processing and Synaptic Plasticity in Presenilin-1 Conditional Knockout Mice , 2001, Neuron.

[37]  Hui Zheng,et al.  Presenilin 1 Negatively Regulates β-Catenin/T Cell Factor/Lymphoid Enhancer Factor-1 Signaling Independently of β-Amyloid Precursor Protein and Notch Processing , 2001, The Journal of cell biology.

[38]  J. Koudstaal,et al.  Clinical relevance of transforming growth factor α, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors , 1998 .

[39]  A. Moser,et al.  ApcMin: a mouse model for intestinal and mammary tumorigenesis. , 1995, European journal of cancer.

[40]  B. de Strooper,et al.  Presenilins and γ-secretase: structure, function, and role in Alzheimer Disease. , 2012, Cold Spring Harbor perspectives in medicine.

[41]  F. Penault-Llorca,et al.  Impact of EGFR expression on colorectal cancer patient prognosis and survival. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.